Effects of Wnt-β-Catenin Signaling and Sclerostin on the Phenotypes of Rat Pheochromocytoma PC12 Cells
Authors:
- Eisaku MorimotoEMEisaku Morimoto
- Kenichi InagakiKIKenichi Inagaki
- Motoshi KomatsubaraMKMotoshi Komatsubara
- Tomohiro TerasakaTTTomohiro Terasaka
- Yoshihiko ItohYIYoshihiko Itoh
- Satoshi FujisawaSFSatoshi Fujisawa
- Erika SasakiESErika Sasaki
- Yuki NishiyamaYNYuki Nishiyama
- Takayuki HaraTHTakayuki Hara
- Jun WadaJWJun Wada
Open Access
- 5 August 2022
- journal article
- research article
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 6 (10) , bvac121
Abstract
Pheochromocytomas and paragangliomas (PPGLs) are classified into 3 major categories with distinct driver genes: pseudohypoxia, kinase signaling, and Wnt-altered subtypes. PPGLs in the Wnt-altered subtype are sporadic and tend to be aggressive with metastasis, where somatic gene fusions affecting mastermind-like 3 (MAML3) and somatic mutations in cold shock domain containing E1 (CSDE1) cause overactivation of Wnt-β-catenin signaling. However, the relation between Wnt-β-catenin signaling and the biological behavior of PPGLs remains unexplored. In rat pheochromocytoma PC12 cells, Wnt3a treatment enhanced cell proliferation and suppressed mRNA expression of tyrosine hydroxylase (TH), the rate-limiting enzyme of catecholamine biosynthesis, and dopamine secretion. We identified the expression of sclerostin in PC12 cells, which is known as an osteocyte-derived negative regulator for Wnt signaling-driven bone formation. Inhibition of endogenous Wnt pathway by XAV939 or sclerostin resulted in attenuated cell proliferation and increased TH expression. Furthermore, Wnt3a pretreatment suppressed bone morphogenetic protein (BMP)-induced Smad1/5/9 phosphorylation whereas BMPs enhanced sclerostin expression in PC12 cells. In the Wnt-altered subtype, the increased Wnt-β-catenin pathway may contribute the aggressive clinical behavior with reduced catecholamine production. Furthermore, upregulated expression of sclerostin by BMPs may explain the osteolytic metastatic lesions observed in metastatic PPGLs.Keywords
This publication has 23 references indexed in Scilit:
- Genotype-Specific Abnormalities in Mitochondrial Function Associate with Distinct Profiles of Energy Metabolism and Catecholamine Content in Pheochromocytoma and ParagangliomaClinical Cancer Research, 2013
- Sclerostin is overexpressed by plasma cells from multiple myeloma patientsAnnals of the New York Academy of Sciences, 2011
- Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBFβ-dependent expression of the Wnt antagonist, sclerostinBreast Cancer Research, 2011
- Myeloma cells suppress osteoblasts through sclerostin secretionBlood Cancer Journal, 2011
- Tankyrase inhibition stabilizes axin and antagonizes Wnt signallingNature, 2009
- Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutationsEndocrine-Related Cancer, 2008
- Wnt/β-Catenin Signaling in Development and DiseaseCell, 2006
- Regulatory Roles of Bone Morphogenetic Proteins and Glucocorticoids in Catecholamine Production by Rat Pheochromocytoma CellsEndocrinology, 2005
- Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt SignalingJournal of Biological Chemistry, 2005
- Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)Human Molecular Genetics, 2001